Literature DB >> 36192668

Association between physical activity and health-related quality of life: time to deterioration model analysis in lung adenocarcinoma.

Jinman Zhuang1, Yuhang Liu1, Xinying Xu1, Yuxin Cai2, Maolin Liu1, Zishan Chen1, Shuyan Yang1, Jianbo Lin3, Zhijian Hu1,4,5, Mingqiang Kang6, Mengxin Lin7, Fei He8,9,10,11.   

Abstract

BACKGROUND AND PURPOSE : Health-related quality of life (HRQoL) is a key aspect of care for cancer survivors that can be improved by physical activity. Our aim was to explore the relationship between physical activity and time to deterioration (TTD) of the HRQoL in patients with lung adenocarcinoma (LUAD).
METHODS: We conducted a hospital-based prospective study. The International Physical Activity Questionnaire long-form (IPAQ-L) was used to investigate the pre-treatment physical activity levels, and the EORTC Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) were used to assess HRQoL at baseline and during follow-up. The QoLR package was used to calculate the HRQoL scores and determine TTD events (minimal clinically important difference=5 points). The effect of physical activity on the HRQoL was assessed using Cox regression analysis.
RESULTS: For EORTC QLQ-C30, TTD events of physical functioning (PF) and dyspnea (DY) in functional scales and symptom scales were the most common during follow-up. Pre-treatment physical activity was found to significantly delay TTD of insomnia (HR=0.635, 95%CI: 0.437-0.922, P=0.017) and diarrhea (HR=0.475, 95%CI: 0.291-0.774, P=0.003). For EORTC QLQ-LC13 scales, deterioration of dyspnea (LC-DY) was the most common event. Physical activity was found to delay the TTD of dyspnea (HR=0.654, 95%CI: 0.474-0.903, P=0.010), sore mouth (HR=0.457, 95%CI: 0.244-0.856, P=0.015), and dysphagia (HR=0.315, 95%CI: 0.172-0.580, P<0.001).
CONCLUSIONS: Pre-treatment physical activity of LUAD patients may delay the TTD of multiple HRQoL indicators in EORTC QLQ-C30 and EORTC QLQ-LC13. IMPLICATION FOR CANCER SURVIVORS: Health-related quality of life (HRQoL) is a key aspect of care for cancer survivors (someone who is living with or beyond cancer), that can be improved by physical activity. Our aim was to explore the relationship between physical activity and time to deterioration (TTD) of the HRQoL in patients with lung adenocarcinoma (LUAD).
© 2022. The Author(s).

Entities:  

Keywords:  Health-related quality of life; Lung adenocarcinoma; Physical activity; Time to deterioration

Year:  2022        PMID: 36192668     DOI: 10.1007/s11764-022-01259-z

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.062


  27 in total

1.  Quality of life in lung cancer patients.

Authors:  C Gridelli; F Perrone; F Nelli; S Ramponi; F De Marinis
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 2.  Developing a Quality of Cancer Survivorship Care Framework: Implications for Clinical Care, Research, and Policy.

Authors:  Larissa Nekhlyudov; Michelle A Mollica; Paul B Jacobsen; Deborah K Mayer; Lawrence N Shulman; Ann M Geiger
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

3.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

4.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

5.  Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Henri G Colt; Septimiu D Murgu; Robert J Korst; Christopher G Slatore; Michael Unger; Silvia Quadrelli
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

6.  Lung cancer recurrence and mortality outcomes over a 10-year period using a multidisciplinary team approach.

Authors:  Barbara Nemesure; Denise Albano; Thomas Bilfinger
Journal:  Cancer Epidemiol       Date:  2020-09-04       Impact factor: 2.984

7.  Physical activity for people with lung cancer.

Authors:  Lara Edbrooke; Catherine L Granger; Linda Denehy
Journal:  Aust J Gen Pract       Date:  2020-04

8.  Four-year effects of exercise on fatigue and physical activity in patients with cancer.

Authors:  Lenja Witlox; Anouk E Hiensch; Miranda J Velthuis; Charlotte N Steins Bisschop; Maartje Los; Frans L G Erdkamp; Haiko J Bloemendal; Marlies Verhaar; Daan Ten Bokkel Huinink; Elsken van der Wall; Petra H M Peeters; Anne M May
Journal:  BMC Med       Date:  2018-06-08       Impact factor: 8.775

Review 9.  Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?

Authors:  Massimo Lanza; Sara Pilotto; Alice Avancini; Giulia Sartori; Anastasios Gkountakos; Miriam Casali; Ilaria Trestini; Daniela Tregnago; Emilio Bria; Lee W Jones; Michele Milella
Journal:  Oncologist       Date:  2019-11-26

10.  The effect of enhancing quality of life in patients intervention for advanced lung cancer: Protocol for a randomized clinical study.

Authors:  Xianhong Li; Ke Qin; Chunyan Yuan; Shiqiang Song
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.